Intravenous immunoglobulins for the management of Stevens-Johnson syndrome with minimal skin manifestations.
Here we describe the successful use of intravenous immunoglobulin (IVIG) in the management of mycoplasma-induced, atypical Stevens-Johnson syndrome (SJS) with minimal skin manifestations. The patient was successfully managed with high-dose IVIG 0.5 g/kg for 4 consecutive days. No complications were noted. IVIG may be useful in the management of mycoplasma-induced SJS.
Zipitis
Christos S
CS
Jenny Lind Children's Department, Norfolk and Norwich University Hospital, Colney Lane, Norwich, NR4 7UY, UK. czipitis@hotmail.com
Thalange
Nandu
N
D000293:Adolescent; D003937:Diagnosis, Differential; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D009177:Mycoplasma pneumoniae / Q000302:isolation & purification / Q000472:pathogenicity*; D013262:Stevens-Johnson Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology
D016756:Immunoglobulins, Intravenous